Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100906 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Marco Galvez-Nino und 20 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Universidad Peruana Cayetano Heredia, Lima, Peru. Electronic address: marco.galvez.n@upch…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Despite osimertinib being the standard therapy for advanced EGFR T790M mutation positive NSCLC, in many Latin American countries, access to molecular testing and targeted therapies is limited, directly impacting patient outcomes. This study describes the real-world management and outcomes of Peruvian patients with advanced EGFR-mutated NSCLC who develop the T790M mutation. METHODS: We conducted a multicenter retrospective study including patients from nine Peruvian institutions, both public and private, who progressed to first-line EGFR TKI and developed T790M mutation, detected between January 2018 and December 2023. We evaluated demographic, clinico-pathological features and treatment data, including diagnostic pathway, treatment patterns, and survival outcomes. RESULTS: Seventy-eight patients were included; T790M was detected by liquid biopsy in 52.6 % of cases. Median time from progression to T790M detection was 59.5 days (7-244). Osimertinib was administered to 62.8 % of patients after detection, with a median initiation time of 42 days (1-104). Median overall survival (OS) from first-line treatment was 46.6 months for patients who received osimertinib, 23.9 months for those receiving other therapies, and 16.1 months for those without treatment (p = 0.001). Among osimertinib-treated patients, the objective response rate (ORR) was 59.2 %, with a median progression-free survival (PFS) of 15.8 months. Median OS from osimertinib initiation was 16.3 months, significantly longer than for patients receiving other treatments after T790M detection (9.7 months; p = 0.002). CONCLUSIONS: This study confirms the real-world effectiveness of osimertinib in Peruvian patients with advanced EGFR T790M positive NSCLC and highlights the importance of timely detection and access to targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Universidad Peruana Cayetano Heredia, Lima, Peru. Electronic address: marco.galvez.n@upch.pe.
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Universidad Peruana Cayetano Heredia, Lima, Peru.
- Oncosalud - AUNA, Lima, Peru.
- Clínica Internacional, Lima, Peru.
- Instituto Regional de Enfermedades Neoplásicas Centro, Junin, Peru.
- Unidad Oncológica Molecular Peruana, Lima, Peru.
Zitieren
APA
Galvez-Nino, M., Roque, K., Ruiz, R., Namuche, F., Paitan, V., Arrese, T., Zegarra, J., Oblitas, G., Gonzalez, L., Maco, L., Cabrera, M. D. P., Coello, R., Portugal Del Pino, J. L., Ezquerra, J. C., Perez Roca, R., Coanqui, O., Valdiviezo, N., Olivera, M., Vidaurre, T., …, & Mas, L. (2025). Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100906
Vancouver
Galvez-Nino M, Roque K, Ruiz R, Namuche F, Paitan V, Arrese T, et al. Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100906
BibTeX
@article{GalvezNino2025,
author = {Galvez-Nino, Marco and Roque, Katia and Ruiz, Rossana and Namuche, Fernando and Paitan, Victor and Arrese, Tulio and Zegarra, Jorge and Oblitas, George and Gonzalez, Lisde and Maco, Lorenzo and Cabrera, Maria Del Pilar and Coello, Roberto and Portugal Del Pino, Jose Luis and Ezquerra, Juan Carlos and Perez Roca, Rodolfo and Coanqui, Ofelia and Valdiviezo, Natalia and Olivera, Mivael and Vidaurre, Tatiana and Aguilar Cartagena, Alfredo and Mas, Luis},
title = {Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100906}
}
EUVIMED